NCT02964507 2024-08-29Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast CancerGlaxoSmithKlinePhase 1 Terminated124 enrolled 23 charts